IMNM
ImmunomeDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The strongest update since the prior baseline is real primary-source confirmation that varegacestat has moved from planned filing to submitted NDA status on April 29, 2026, with ASCO oral data close behind. If investors gain confidence that the FDA review proceeds normally and the detailed RINGSIDE presentation supports the topline profile, IMNM can still rerate despite the negative deterministic prior.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.3.
What can break
As of May 8, 2026, Immunome's investor-relations news page showed releases through May 5, 2026 but no Q1 2026 financial-results release, leaving the scheduled post-earnings follow-up with limited fresh operating disclosure. [#IR-NEWS-2026-05-08]
Momentum
36
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $30.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $35.58
Why
Momentum36 · Δ7d -6.9
Value41 · Δ7d +0.1
Sentiment58 · Δ7d +7.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
36
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.9
Δ21d
-40.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
58
33% active weight
Current posture
7d trendImproving
Δ7d
+7.3
Δ21d
+17.6
Why this grade
Composite grade D. Momentum 36.0 / Value 41.1 / Sentiment 58.3
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$2.19B
Beta
2.33
Shares Out
110.33M
P/E (TTM) · Derived
-4.0
P/S (TTM)
224.68
P/FCF (TTM) · Derived
-7.94
Rev YoY
-100.0%
EPS YoY
+16.5%
Gross Margin
-
Op Margin
-2419.9%
Net Debt
-$217.3M
Current Ratio
8.90
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology